We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Utilizing Antibodies from Ebola Survivors

Utilizing Antibodies from Ebola Survivors

Utilizing Antibodies from Ebola Survivors

Utilizing Antibodies from Ebola Survivors

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Utilizing Antibodies from Ebola Survivors "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The findings are significant because it helps researchers further understand the immune response to a virus such as Ebola and could lead to treatments for Ebola as well as other related viruses.

The study involved using blood samples from people who had survived the Ebola Bundibugyo strain.

When someone has survived an Ebola infection, they have developed antibodies. The question is, can these antibodies protect against a future infection with the virus and related filoviruses?

Although several mouse antibody-based treatments have provided protection against Ebola Zaire in animal models, there are no available therapeutics based on antibodies from human survivors and no universal treatments against multiple filoviruses, including Ebola Sudan and Ebola Bundibugyo.

In the study, researchers used the blood of seven people who survived Ebola Bundibugyo virus infection during the 2007 outbreak in Uganda to isolate a large number of B cells that produce antibodies, which are the small protein molecules capable of inactivating the virus.

“The work on antibodies isolated from survivors of filovirus infections, including Marburg and Ebola, was started by James Crowe’s laboratory at Vanderbilt University together with our laboratory about 3 years ago,” said virologist Alex Bukreyev, professor at UTMB and co-corresponding author. “In this study, we isolated a remarkably diverse array of virus-specific antibodies, which appeared to bind to various parts of the envelope protein of the virus. Some of the antibodies neutralized not only Ebola Bundibugyo virus, but also Ebola Zaire and Sudan viruses.”

“The quality of these naturally occurring human antibodies as biological drugs to treat the virus infection is remarkable, and we are doubly encouraged because they recognize multiple species of Ebola,” said immunologist James Crowe, Director of the Vanderbilt Vaccine Center.

A portion of the isolated antibodies effectively protected mice and guinea pigs against a lethal Ebola Zaire infection.

“These data provide the basis for understanding the immune response to filovirus infections in humans,” said Bukreyev. “Our results provide a roadmap to developing a single antibody-based treatment effective against not only infections caused by Ebola Zaire virus, but also caused by related filoviruses.”